{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:49:30Z","timestamp":1780487370896,"version":"3.54.1"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The hierarchy of evidence coming from evidence-based medicine favors meta-analyses and randomized controlled trials over observational studies and clinical cases. Nonetheless, in the field of psychiatry, where conditions are much more complex, additional evidence coming from real-world clinical practice is necessary to complement data from these gold standards. Thus, in this systematic review, the aim is to summarize the evidence coming from clinical case reports regarding cariprazine, a third-generation antipsychotic drug that has been approved for the treatment of schizophrenia and bipolar I disorder with manic, depressive or mixed features in adults.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic review was performed using Embase and Pubmed databases searching for English-language cases published in peer-reviewed journals between 2000 January and 2021 September with the following search terms: (cariprazin<jats:sup>*<\/jats:sup> OR \u201crgh-188\u201d OR rgh188 OR vraylar OR reagila) AND (\u201ccase report<jats:sup>*<\/jats:sup>\u201d OR \u201ccase report\u201d\/de OR \u201ccase stud<jats:sup>*<\/jats:sup>\u201d OR \u201ccase study\u201d\/de OR \u201ccase seri<jats:sup>*<\/jats:sup>\u201d).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After the removal of duplicates, 49 articles were retrieved via the search, from which 22 were suitable for this review. These 22 articles encompassed 38 cases from which 71% described patients with schizophrenia, 16% patients with psychotic disorders, 5% patients with mood disorder and 8% described patients with other disorders such as Wernicke-Korsakoff syndrome, borderline personality disorder and obsessive-compulsive disorder with paranoid schizophrenia. The median age of patients was 31, and half of them were female. The majority of patients (76%) started cariprazine with 1.5 mg\/day, and the most common maintenance dose was 4.5 mg\/day (34%) and 3.0 mg\/day (29%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Cariprazine was found to be safe and effective in a wide range of psychiatric conditions with different symptom profiles from acute psychotic symptoms through addiction to negative and cognitive symptoms. The results are in-line with the established evidence from clinical trials, however, they also show how cariprazine can be successfully utilized for treating certain symptoms irrespective of the indication.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2022.827744","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T15:26:50Z","timestamp":1647530810000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies"],"prefix":"10.3389","volume":"13","author":[{"given":"R\u00e9ka","family":"Csehi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia Borb\u00e1la","family":"Dombi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1ria Judit","family":"Moln\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11017-007-9029-x","article-title":"Does evidence-based medicine apply to psychiatry?","volume":"28","author":"Gupta","year":"2007","journal-title":"Theor Med Bioeth."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence \u2014 what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/jama.2018.10136","article-title":"Real-world evidence and real-world data for evaluating drug safety and effectiveness","volume":"320","author":"Corrigan-Curay","year":"2018","journal-title":"J Am Med Assoc."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1002\/pds.5167","article-title":"The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: case studies","volume":"29","author":"Radawski","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B5","year":""},{"key":"B6","unstructured":""},{"key":"B7","unstructured":""},{"key":"B8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3\/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J Pharmacol Exp Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/DDDT.S95100","article-title":"Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)","volume":"10","author":"Nakamura","year":"2016","journal-title":"Drug Des Devel Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.2147\/DDDT.S188760","article-title":"Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine","volume":"13","author":"Kiss","year":"2019","journal-title":"Drug Des Devel Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e1574","DOI":"10.4088\/JCP.15m09997","article-title":"Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial","volume":"76","author":"Durgam","year":"2015","journal-title":"J Clin Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","article-title":"An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial","volume":"152","author":"Durgam","year":"2014","journal-title":"Schizophr Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an International, Phase III Clinical Trial","volume":"35","author":"Kane","year":"2015","journal-title":"J Clin Psychopharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/YIC.0000000000000110","article-title":"Cariprazine in the treatment of schizophrenia: a proof-of-concept trial","volume":"2","author":"Durgam","year":"2016","journal-title":"Int Clin Psychopharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1017\/S1092852917000220","article-title":"Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study","volume":"23","author":"Cutler","year":"2018","journal-title":"CNS Spectr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00213-016-4450-3","article-title":"Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study","volume":"234","author":"Durgam","year":"2017","journal-title":"Psychopharmacology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.schres.2016.06.030","article-title":"Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"3","author":"Durgam","year":"2016","journal-title":"Schizophr Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial","volume":"389","author":"N\u00e9meth","year":"2017","journal-title":"Lancet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1176\/appi.ajp.2015.15020164","article-title":"An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression","volume":"173","author":"Durgam","year":"2016","journal-title":"Am J Psychiatry."},{"key":"B20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1176\/appi.ajp.2018.18070824","article-title":"Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study","volume":"176","author":"Earley","year":"2019","journal-title":"Am J Psychiatry."},{"key":"B21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/YIC.0000000000000307","article-title":"Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"35","author":"Yatham","year":"2020","journal-title":"Int Clin Psychopharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/bdi.12852","article-title":"Efficacy and safety of cariprazine in bipolar I depression: a double-blind, placebo-controlled phase 3 study","volume":"22","author":"Earley","year":"2020","journal-title":"Bipolar Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/bdi.12238","article-title":"The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial","volume":"17","author":"Durgam","year":"2015","journal-title":"Bipolar Disord."},{"key":"B24","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jad.2014.11.018","article-title":"Cariprazine in the treatment of acute mania in bipolar i disorder: a double-blind, placebo-controlled, Phase III trial","volume":"174","author":"Sachs","year":"2015","journal-title":"J Affect Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.4088\/JCP.14m09081","article-title":"Efficacy and safety of low- and high-dose Cariprazine in acute and mixed mania associated with bipolar i disorder: a double-blind, placebo-controlled study","volume":"76","author":"Calabrese","year":"2015","journal-title":"J Clin Psychiatry."},{"key":"B26","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jad.2017.08.040","article-title":"The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: a 16-week open-label study","volume":"225","author":"Ketter","year":"2018","journal-title":"J Affect Disord."},{"key":"B27","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4088\/JCP.15m10070","article-title":"Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder","volume":"77","author":"Durgam","year":"2016","journal-title":"J Clin Psychiatry."},{"key":"B28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/YIC.0000000000000235","article-title":"Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Fava","year":"2018","journal-title":"Int Clin Psychopharmacol."},{"key":"B29","first-page":"62","article-title":"Cariprazine augmentation to antidepressant therapy in major depressive disorder: results of a randomized, double-blind, placebo-controlled trial","volume":"48","author":"Earley","year":"2018","journal-title":"Psychopharmacol Bull."},{"key":"B30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/YIC.0000000000000246","article-title":"Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder","volume":"34","author":"Vieta","year":"2019","journal-title":"Int Clin Psychopharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/YIC.0000000000000351","article-title":"The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study","volume":"36","author":"Rancans","year":"2021","journal-title":"Int Clin Psychopharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045125320905752","article-title":"Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data","volume":"10","author":"Stahl","year":"2020","journal-title":"Ther Adv Psychopharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fpsyt.2019.00070","article-title":"Switch to cariprazine in patients with schizophrenia with side effects\/medical comorbidities","volume":"54","author":"Amore","year":"2019","journal-title":"Riv Psichiatr."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.2147\/NDT.S315653","article-title":"Cariprazine: patients with treatment-resistant schizophrenia","volume":"17","author":"Aubel","year":"2021","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B36","first-page":"11","article-title":"Clinical experiences with cariprazine in schizophrenic patients with comorbid substance abuse","volume":"5","author":"Carmassi","year":"2019","journal-title":"Evid based Psyxhiatr Care."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyt.2021.727666","article-title":"Case report: cariprazine in a patient with schizophrenia, substance abuse, and cognitive dysfunction","volume":"12","author":"Rodriguez Cruz","year":"2021","journal-title":"Front Psychiatry."},{"key":"B38","doi-asserted-by":"publisher","first-page":"174","DOI":"10.9758\/cpn.2021.19.1.174","article-title":"Cariprazine add-on in inadequate clozapine response: a report on two cases","volume":"19","author":"De Berardis","year":"2021","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"B39","first-page":"15","article-title":"Clinical experiences with cariprazine in patients with early psychosis","volume":"5","author":"De Berardis","year":"2019","journal-title":"Evid Based Psyxhiatr Care."},{"key":"B40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/YIC.0000000000000284","article-title":"Rapid improvement of obsessive-compulsive disorder associated with schizophrenia with cariprazine add-on in a subject under paliperidone long-acting injection: a case report","volume":"35","author":"De Berardis","year":"2020","journal-title":"Int Clin Psychopharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/WNF.0000000000000409","article-title":"Resolution of citalopram sexual adverse effects with low dose of cariprazine: a case report","volume":"43","author":"Dieci","year":"2020","journal-title":"Clin Neuropharmacol."},{"key":"B42","first-page":"8","article-title":"Experiences of switching to cariprazine","volume":"5","author":"Di Sciascio","year":"2019","journal-title":"Evid Based Psyxhiatr Care."},{"key":"B43","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/pcn.13094","article-title":"Cariprazine treatment of borderline personality disorder: a case report","volume":"74","author":"Grant","year":"2020","journal-title":"Psychiatry Clin Neurosci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/JCP.0000000000001074","article-title":"Metabolic syndrome reversal with cariprazine","volume":"39","author":"Halaris","year":"2019","journal-title":"J Clin Psychopharmacol."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4084","article-title":"A case series of serious and unexpected adverse drug reactions under treatment with cariprazine","author":"Heck","year":"2021","journal-title":"Clin Case Reports."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756286420938972","article-title":"Wernicke\u2013Korsakoff syndrome associated with mtDNA disease","volume":"13","author":"Jimoh","year":"2020","journal-title":"Ther Adv Neurol Disord."},{"key":"B47","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/WNF.0000000000000301","article-title":"Urinary retention associated with cariprazine: a case report","volume":"41","author":"Kapulsky","year":"2018","journal-title":"Clin Neuropharmacol."},{"key":"B48","first-page":"11","article-title":"A clinical case series of switching to cariprazine in schizophrenic patients with partial response to other antipsychotics","volume":"54","author":"Mencacci","year":"2019","journal-title":"Riv Psichiatr."},{"key":"B49","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3389\/fphar.2020.00477","article-title":"Early-onset schizophrenia with predominantly negative symptoms: a case study of a drug-naive female patient treated with cariprazine","volume":"11","author":"Molnar","year":"2020","journal-title":"Front Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/NDT.S298005","article-title":"Cariprazine in three acute patients with schizophrenia: a real-world experience","volume":"17","author":"Montes","year":"2021","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2147\/NDT.S303817","article-title":"Decline in psychotic symptoms in addition to cardiac and metabolic safety with cariprazine after poor response to previous antipsychotic treatments \u2013 a series of two cases","volume":"17","author":"M\u00fcller","year":"2021","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/10550887.2021.1945398","article-title":"Remission of persistent methamphetamine-induced psychosis after cariprazine therapy: presentation of a case report","volume":"1","author":"Ricci","year":"2021","journal-title":"J Addict Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1055\/a-0988-2039","article-title":"Cariprazine","volume":"39","author":"Riedesser","year":"2020","journal-title":"Nervenheilkunde."},{"key":"B54","article-title":"Cariprazine may decrease substance abuse in patients with bipolar I disorder","volume":"36","author":"Sanders","year":"2019","journal-title":"Psychiatr Times."},{"key":"B55","first-page":"16","article-title":"A clinical case series of switching to cariprazine in schizophrenic patients with partial response to other antipsychotics","volume":"54","author":"Vita","year":"2019","journal-title":"Riv Psichiatr."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12991-020-00305-3","article-title":"Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel","volume":"19","author":"Fagiolini","year":"2020","journal-title":"Ann Gen Psychiatry."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyt.2021.770234","article-title":"Dosing cariprazine within and beyond clinical trials \u2013 recommendations for the treatment of schizophrenia","volume":"12","author":"Rancans","year":"2022","journal-title":"Front Psychiatry."},{"key":"B58","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.euroneuro.2018.10.008","article-title":"Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II\/III studies","volume":"29","author":"Marder","year":"2019","journal-title":"Eur Neuropsychopharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jad.2019.07.020","article-title":"Cariprazine for the treatment of bipolar mania with mixed features: a post hoc pooled analysis of 3 trials","volume":"257","author":"McIntyre","year":"2019","journal-title":"J Affect Disord."},{"key":"B60","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1007\/s00213-016-4382-y","article-title":"Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3\/D2 receptor ligand [11C]-(+)-PHNO","volume":"233","author":"Girgis","year":"2016","journal-title":"Psychopharmacology."},{"key":"B61","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00213-011-2343-z","article-title":"Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography","volume":"218","author":"Seneca","year":"2011","journal-title":"Psychopharmacology."},{"key":"B62","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science (80-)."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1126\/science.1145194","article-title":"Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons","volume":"188","author":"Seeman","year":"1975","journal-title":"Science (80-)."},{"key":"B64","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/mp.2017.16","article-title":"The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment","volume":"22","author":"Ashok","year":"2017","journal-title":"Mol Psychiatry."},{"key":"B65","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4088\/JCP.15m10192","article-title":"The effect of Cariprazine on hostility associated with schizophrenia: Post hoc analyses from 3 randomized controlled trials","volume":"77","author":"Citrome","year":"2016","journal-title":"J Clin Psychiatry."},{"key":"B66","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1017\/S1092852916000043","article-title":"Mechanism of action of cariprazine","volume":"21","author":"Stahl","year":"2016","journal-title":"CNS Spectr."},{"key":"B67","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1017\/S1092852917000426","article-title":"Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors","volume":"22","author":"Stahl","year":"2017","journal-title":"CNS Spectr."},{"key":"B68","article-title":"The treatment of bipolar disorder: integrative clinical strategies and future directions","author":"Carvalho","year":"2017"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.2147\/NDT.S76700","article-title":"Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analyses","volume":"11","author":"Bortolato","year":"2015","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eurpsy.2019.01.015","article-title":"The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors","volume":"58","author":"Fleischhacker","year":"2019","journal-title":"Eur Psychiatry."},{"key":"B71","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1017\/S1092852921000213","article-title":"Effects of cariprazine on cognition in patients with bipolar mania or mixed states: Post hoc analysis from 3 randomized, controlled phase III studies","volume":"26","author":"McIntyre","year":"2021","journal-title":"CNS Spectr."},{"key":"B72","first-page":"78","article-title":"Efficacy of cariprazine on cognitive symptoms in patients with bipolar depression","volume":"44","author":"McIntyre","year":"2019","journal-title":"Neuropsychopharmacology."},{"key":"B73","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.pnpbp.2013.08.012","article-title":"What is the role of the D3 receptor in addiction? A mini review of PET studies with [11C]-(+)-PHNO","volume":"52","author":"Payer","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B74","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00213-012-2906-7","article-title":"Cariprazine (RGH-188), a D3-preferring dopamine D 3\/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats","volume":"226","author":"Rom\u00e1n","year":"2013","journal-title":"Psychopharmacology."},{"key":"B75","unstructured":"2018"},{"key":"B76","unstructured":"2021"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyt.2021.803208","article-title":"Reducing addiction in bipolar disorder via hacking the dopaminergic system","volume":"12","author":"Grunze","year":"2021","journal-title":"Front Psychiatry."},{"key":"B78","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1017\/S1092852919001287","article-title":"Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: Post hoc analysis of 3 randomized, placebo-controlled studies","volume":"25","author":"Mcintyre","year":"2019","journal-title":"CNS Spectr."},{"key":"B79","volume-title":"Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th ed.","author":"Stahl","year":"2013"},{"key":"B80","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4088\/JCP.7075su1c.02","article-title":"Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE Global Survey","volume":"70","author":"McIntyre","year":"2009","journal-title":"J Clin Psychiatry."},{"key":"B81","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1007\/s12325-021-01797-5","article-title":"Cariprazine, A broad-spectrum antipsychotic for the treatment of schizophrenia: pharmacology, efficacy, and safety","volume":"38","author":"Laszlovszky","year":"2021","journal-title":"Adv Ther."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1080\/03007995.2021.1932446","article-title":"The efficacy of cariprazine on function in patients with bipolar depression: a post hoc analysis of a randomized controlled trial","volume":"37","author":"Vieta","year":"2021","journal-title":"Curr Med Res Opin."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11920-017-0752-3","article-title":"Treatment of functional impairment in patients with bipolar disorder","volume":"19","author":"Sanchez-Moreno","year":"2017","journal-title":"Curr Psychiatry Rep."},{"key":"B84","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2147\/NDT.S301225","article-title":"Safety and tolerability of cariprazine in patients with schizophrenia: a pooled analysis of eight phase II\/III studies","volume":"17","author":"Barab\u00e1ssy","year":"2021","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B85","first-page":"292","article-title":"Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications","volume":"4","author":"Riordan","year":"2011","journal-title":"Am Heal Drug Benefits."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12888-017-1459-z","article-title":"The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis","volume":"17","author":"Nasrallah","year":"2017","journal-title":"BMC Psychiatry."},{"key":"B87","doi-asserted-by":"publisher","first-page":"627","DOI":"10.4088\/JCP.08r04210","article-title":"Akathisia: an updated review focusing on second-generation antipsychotics","volume":"70","author":"Kane","year":"2009","journal-title":"J Clin Psychiatry."},{"key":"B88","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2174\/1570159X14666161208153644","article-title":"Revisiting antipsychotic-induced Akathisia: current issues and prospective challenges","volume":"15","author":"Salem","year":"2017","journal-title":"Curr Neuropharmacol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-0500-7-264","article-title":"The clinical case report: a review of its merits and limitations","volume":"7","author":"Nissen","year":"2014","journal-title":"BMC Res Notes."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.827744\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T15:27:07Z","timestamp":1647530827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.827744\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":89,"alternative-id":["10.3389\/fpsyt.2022.827744"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.827744","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"article-number":"827744"}}